Cholangiocarcinoma, whether arising from the intrahepatic or extrahepatic biliary system, is a rare but devastating malignancy. Prognosis is poor, with 5-year overall survival rates <5% including patients undergoing surgery. [1] [2] [3] Resection is the only curative treatment; however, only 30% of patients present at a resectable stage, and intrahepatic recurrence is common even after complete resection. 4, 5 Survival, therefore, remains low even for postoperative patients, ranging from 8% to 47% at 5 years. 1 It is also appropriate to recognize that the epidemiology, management, and prognosis of intrahepatic cholangiocarcinoma (ICC) and extrahepatic cholangiocarcinoma (ECC) differ, such that they must be considered separately when evaluating new treatment strategies. More than 90% of cholangiocarcinomas are adenocarcinomas, and most tumors arise at the bifurcation of the hepatic ducts (Klatskin tumors) or from the common bile duct; ICC therefore constitutes only 5 to 10% of all cholangiocarcinomas.
1 Cancers of the biliary tract can be classified by a variety of means. The most frequently used staging systems include the American Joint Committee on Cancer (AJCC)/International Union Against Cancer and a Japanese staging system. 6, 7 The AJCC system has been criticized for failing to consider hepatocellular carcinoma (HCC) and cholangiocarcinoma separately; the seventh and most recent edition now addresses this issue.
6,8
In the United States, the incidence of ICC is rising, and patients with ICC tend to present at a later stage than those with ECC (the incidence of which is actually decreasing).
3
These factors underscore the importance of refining and improving nonsurgical treatment modalities in the treatment of ICC. The scope of this review is limited to the treatment of intrahepatic cholangiocarcinoma, with a focus on intraarterial liver-directed therapies.
Traditional palliative approaches to ICC include biliary decompression, systemic chemotherapy, and external radiation therapy, with symptom control and improved quality of life the primary treatment goals. The effectiveness of these modalities is limited. In fact, a standard chemotherapy regimen was not uniformly established until a recent 410-patient phase 3 trial identified the combination of cisplatin and
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gemcitabine as superior to gemcitabine alone (median overall survival of 11.7 months compared with 8.1 months, respectively). 9 However, only 80 patients (20%) in this trial had intrahepatic tumors. In another study, combination therapy with gemcitabine and oxaliplatin has also been reported with favorable results (with ICC representing 45% of the cohort).
10
Evidence supporting the use of external radiation therapy in unresectable ICC is limited, with many prior studies addressing ECC or gallbladder carcinoma. A series including 46 patients with ICC using high-dose conformal radiation therapy demonstrated a median survival of 13.3 months; however, patients also received concurrent continuous infusion of floxuridine via implanted arterial ports as part of the treatment regimen.
11 More recently, stereotactic body radiotherapy was used in 26 patients with Klatskin tumors and one patient with ICC, resulting in an overall median survival of 10.6 months. However, six patients developed duodenal ulceration, all severely symptomatic requiring transfusion and/or hospitalization, and three patients developed duodenal stenosis, two of whom required endoscopic dilation.
12
Percutaneous tumor ablation including radiofrequency and microwave ablation have also been reported, but they have a limited role in advanced ICC because these therapies are suited to small peripheral tumors.
13-17
Intra-arterial therapies primarily consist of chemotherapy-based modalities including conventional transcatheter arterial chemoembolization (TACE), transcatheter arterial chemoinfusion (TACI), or drug-eluding bead transcatheter arterial chemoembolization (DEB-TACE Intra-Arterial Liver-Directed Therapies
Transcatheter Arterial Chemoembolization
Chemoembolization strategies use high-dose chemotherapy delivered in a selective manner to hypervascular liver tumors via catheter injection from the hepatic artery, followed by A series by Gusani et al included 42 patients treated with TACE from 2001 to 2007. Several regimens were used including gemcitabine alone (n ¼ 18), gemcitabine followed by cisplatin (n ¼ 2), gemcitabine followed by oxaliplatin (n ¼ 4), and gemcitabine and cisplatin in combination (n ¼ 14). 21 Patients with ECOG PS >1 were excluded. Extra- 
Drug-Eluting Bead Chemoembolization
Drug-eluting bead (DEB) therapy consists of highly absorbent microspheres mixed with high doses of chemotherapy, prior to hepatic arterial delivery similar to conventional TACE procedures. With DEB-TACE, more favorable dose delivery and reduced systemic toxicity have been achieved in animal models and in patients with hepatocellular carcinoma when compared with conventional chemoembolization. [25] [26] [27] Multiple DEB platforms are available that have been used to deliver both doxorubicin and oxaliplatin chemotherapy regimens; only a few series to date have investigated DEB-TACE therapy in the treatment of ICC (►Table 2). Aliberti et al were the first to report 11 patients who underwent TACE with DC Beads (Biocompatibles UK, Surrey, UK) loaded with doxorubicin. 28 All patients in this series had received prior systemic chemotherapy and/or hepatic resection. Patient characteristics, such as severity of liver disease, presence of extrahepatic disease, and tumor vascularity, were not described. A median of three treatment sessions was performed. Median survival was 13 months following the first DEB-TACE session. Another small series by Poggi et al reported nine patients treated with microspheres (HepaSphere, Biosphere Medical, Roissy CDG Cedex, France) mixed with oxaliplatin, followed by systemic chemotherapy (oxaliplatin and gemcitabine).
29
Patients who received DEB-TACE were compared with a historical control receiving only systemic chemotherapy. Only one patient in the systemic chemotherapy arm had Child-Pugh class B liver disease; patients in both arms otherwise had class A liver disease. Furthermore, extrahepatic disease was used as an exclusion criteria. With this in mind, an impressive median survival of 30 months was observed in the DEB-TACE arm, compared with 12.7 months for systemic chemotherapy alone (p ¼ 0.004).
More recently, Kuhlmann et al compared treatment of 26 patients with unresectable cholangiocarcinoma with irinotecan-eluting PVA microspheres (DC/LC Bead, Biocompatibles, Farnham, UK) to 10 patients treated with conventional TACE (mitomycin and Gelfoam). 30 Comparison was also made with 31 patients treated with systemic chemotherapy only, consisting of gemcitabine and oxaliplatin. 10 Approximately 20%
of patients in the chemoembolization arms had received prior systemic chemotherapy. Median overall survival was 11.7 months in the DEB-TACE group, 5.7 months in the conventional TACE group, and 11.0 months in the systemic chemotherapy group. Precise comparison between these groups is difficult, however, because the primary tumor site varied substantially between the groups, with 55% of tumors either extrahepatic or confined to the gallbladder in the systemic chemotherapy arm, compared with 90% of tumors located within intrahepatic bile ducts in the chemoembolization arms. Extrahepatic disease was present in 40% of patients treated with chemoembolization; 90% of patients treated with systemic chemotherapy had extrahepatic disease. 
Yttrium-90 Radioembolization

Conclusion
Cholangiocarcinoma represents a spectrum of rare biliary tract cancers with an increasing incidence of ICC. The disease overall carries a poor prognosis, and most patients with ICC are unresectable at presentation. Several treatment options exist for unresectable ICC, with liver-directed therapies representing a favorable approach for palliative treatment given their targeted nature. Many series describing intra-arterial approaches have been reported, however, patient demographics vary substantially between studies, making exact comparison difficult. Prospective and/or randomized trials are difficult to perform due to the rarity of the disease. However, response rates and survival for ICC appear to be higher for liver-directed therapies than those reported with modern combination chemotherapy regimens. Future studies should strive to analyze the various subgroups of cholangiocarcinoma independently, principally ICC and ECC, such that useful comparisons can be made between liver-directed therapy, systemic therapy, and combined approaches.
